MedTrace Logo

Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

NCT05105100 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-04-06

Study results available
· View outcomes & findings →

Summary

This is a non-therapeutic study assessing peripheral T cell determinants of response and resistance to immunotherapy in patients with advanced melanoma.The hypothesis is that systemic T cells traffic into the tumor microenvironment (TME) can predict response and resistance to immunotherapy. These systemic tumor directed T cells can be defined by tumor/blood small conditional RNA (scRNA) using T cell receptor (TCR) as a barcode and can help predict response to Programmed death-1 (PD-1) therapy.

Conditions

Interventions

PROCEDURE

Biopsy

Tumor tissue collection

PROCEDURE

Biospecimen Collection

Intravenously Blood draw

Sponsors & Collaborators

Principal Investigators

  • Adil Daud, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-29
Primary Completion
2025-09-15
Completion
2025-09-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05105100 on ClinicalTrials.gov